AMPK/SIRT1/PGC‐1α Signaling Pathway: Molecular Mechanisms and Targeted Strategies From Energy Homeostasis Regulation to Disease Therapy
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Background: The AMPK/SIRT1/PGC‐1α pathway serves as a central regulator of cellular energy homeostasis, coordinating metabolic stress responses, epigenetic modifications, and transcriptional programs. Its dysfunction is implicated in the pathogenesis of a wide spectrum of complex modern diseases, spanning neurodegeneration, metabolic syndromes, and chronic inflammatory conditions. This review examines the pathway's role as an integrative hub and its potential as a therapeutic target. Methods: We synthesize current mechanistic evidence from molecular, cellular, and preclinical studies to elucidate the pathway's operational logic and the consequences of its dysregulation. The analysis is structured around key disease paradigms—including Alzheimer's disease, Parkinson's disease, diabetes, cardiovascular injury, stroke, and chronic kidney disease—to dissect its tissue‐specific pathophysiological impacts. Results: The AMPK/SIRT1/PGC‐1α axis operates through a core positive feedback loop: AMPK activation elevates NAD+, thereby activating SIRT1, which in turn deacetylates and activates PGC‐1α to drive mitochondrial biogenesis and function, further reinforcing SIRT1 activity. Disruption of this cascade manifests in disease‐specific mechanisms: promoting Aβ production via BACE1/γ‐secretase in Alzheimer's; impairing α‐synuclein clearance in Parkinson's; disrupting GLUT4 translocation and insulin signaling in diabetes; exacerbating oxidative damage and mitochondrial dysfunction in cardiovascular and neuronal injury; and accelerating fibrosis and sustained inflammation in renal and pulmonary diseases via NLRP3 and TGF‐β/Smad3 signaling. Conclusions: The AMPK/SIRT1/PGC‐1α pathway represents a cornerstone target at the intersection of metabolism, aging, and disease. Current therapeutic strategies—including pharmacological activators (e.g., metformin, SRT1720), natural compounds (e.g., resveratrol), lifestyle interventions (e.g., exercise, caloric restriction), and emerging technologies (e.g., gene editing, exosomal miRNAs)—offer multidimensional avenues for intervention. Future research must prioritize elucidating tissue‐specific regulatory mechanisms, such as AMPK isoform diversity and PGC‐1α interactome dynamics, to enable precision therapeutics and successful clinical translation for a range of complex disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression
Shackelford, D. B., & Shaw, R. J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2676 · Cited by 1,943 · cited 2×
“Under metabolic stress, LKB1 phosphorylates AMPK during energy deprivation [21].”
Challenges in the diagnosis of Parkinson's disease
Tolosa, E., Garrido, A., Scholz, S. W., & Poewe, W. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00030-2 · Cited by 1,874 · cited 1×
“…by progressive loss of dopaminergic neurons in the substantia nigra, accumulation of α-synuclein aggregates (Lewy bodies), and gliosis, with pathogenesis involving complex interactions among mitochondrial dysfunction, oxidative stress, protein homeostasis disruption, and neuroinflammation [90, 91].”
Osteoarthritis: pathogenic signaling pathways and therapeutic targets
Yao, Q., Wu, X., Tao, C., Gong, W., Chen, M., Qu, M., Zhong, Y., He, T., Chen, S., & Xiao, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01330-w · Cited by 1,194
AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress
Jeon, S.-M., Chandel, N. S., & Hay, N. (2012) · Nature · doi:10.1038/nature11066 · Cited by 1,132
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039
AMPK activators: mechanisms of action and physiological activities
Kim, J., Yang, G., Kim, Y., Kim, J., & Ha, J. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.16 · Cited by 817
SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase
Hou, X., Xu, S., Maitland-Toolan, K. A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T. J., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802187200 · Cited by 778 · cited 1×
“For tau pathology modulation, SIRT1-mediated Tau deacetylation effectively prevents its hyperphosphorylation and subsequent neurofibrillary tangle formation [86, 87].”
Contemporary medical, device, and surgical therapies for obesity in adults
Perdomo, C. M., Cohen, R. V., Sumithran, P., Clément, K., & Frühbeck, G. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02403-5 · Cited by 738 · cited 1×
“Obesity, primarily caused by chronic energy intake exceeding expenditure, leads to excessive fat accumulation [129].”
Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus
Foretz, M., Guigas, B., & Viollet, B. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0242-2 · Cited by 686 · cited 1×
“It enhances metabolic function by promoting glucose uptake in liver, muscle and adipose tissue while suppressing hepatic gluconeogenesis, establishing its position as a first-line diabetes therapy [208].”
PGC-1α Is a Master Regulator of Mitochondrial Lifecycle and ROS Stress Response
Abu Shelbayeh, O., Arroum, T., Morris, S., & Busch, K. B. (2023) · Antioxidants · doi:10.3390/antiox12051075 · Cited by 552
The Role of SIRT1 on DNA Damage Response and Epigenetic Alterations in Cancer
Alves-Fernandes, D. K., & Jasiulionis, M. G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133153 · Cited by 385
Systemic pan-AMPK activator MK-8722 improves glucose homeostasis but induces cardiac hypertrophy
Myers, R. W., Guan, H.-P., Ehrhart, J., Petrov, A., Prahalada, S., Tozzo, E., Yang, X., Kurtz, M. M., Trujillo, M., Gonzalez Trotter, D., et al. (2017) · Science · doi:10.1126/science.aah5582 · Cited by 346
Ren, H., Shao, Y., Wu, C., Ma, X., Lv, C., & Wang, Q. (2020) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110628 · Cited by 313 · cited 1×
“In diabetic kidney disease specifically, metformin activates the AMPK/SIRT1 axis to mitigate oxidative damage and prevent excessive autophagy [210].”
Meng, Q., Qi, X., Fu, Y., Chen, Q., Cheng, P., Yu, X., Sun, X., Wu, J., Li, W., Zhang, Q., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112326 · Cited by 145 · cited 1×
“…diabetic vascular endothelial dysfunction through the GLUT1 inhibition–AMPK activation– PGC-1α upregulation cascade [239], while mulberry flavonoids activate the AMPK- PGC-1α axis to enhance skeletal muscle glucose uptake and mitochondrial function, thereby reversing insulin resistance [240].”
Song, J., Liu, J., Cui, C., Hu, H., Zang, N., Yang, M., Yang, J., Zou, Y., Li, J., Wang, L., et al. (2023) · Journal of Cachexia, Sarcopenia and Muscle · doi:10.1002/jcsm.13177 · Cited by 118 · cited 1×
“In metabolic disorders, umbilical cord stem cell-derived exosomes activate AMPK to facilitate muscle recovery in diabetes [257], while Lycium berry nanoparticles enhance muscle performance by elevating AMPK/SIRT1/PGC-1α pathway activity [258].”
SIRT1 protects against cigarette smoke-induced lung oxidative stress via a FOXO3-dependent mechanism
Yao, H., Sundar, I. K., Ahmad, T., Lerner, C., Gerloff, J., Friedman, A. E., Phipps, R. P., Sime, P. J., McBurney, M. W., Guarente, L., et al. (2014) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00323.2013 · Cited by 104
Brain-specific repression of AMPKα1 alleviates pathophysiology in Alzheimer’s model mice
Zimmermann, H. R., Yang, W., Kasica, N. P., Zhou, X., Wang, X., Beckelman, B. C., Lee, J., Furdui, C. M., Keene, C. D., & Ma, T. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133982 · Cited by 86
Metformin induces PGC‐1α expression and selectively affects hepatic PGC‐1α functions
Aatsinki, S., Buler, M., Salomäki, H., Koulu, M., Pavek, P., & Hakkola, J. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12585 · Cited by 85
Metadata
- Authors
- Chen, J., Liu, B., Yao, X., Yang, X., Sun, J., Yi, J., Xue, F., Zhang, J., Shen, Y., Chen, B., & Sun, H.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2025-11
- Volume
- 31
- Issue
- 11
- Pages
- e70657-e70657
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W4416457839
- Cited by
- 190
- References
- 18
- FWCI
- 98.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.